CallihanDahlgren554

The researchers assessed four drugs: Allegra, Arava, Amaryl and Zithromax. In the second 1 / 2 of 2005, each one of these drugs come to an end of patent protection. Their simple equivalents were purchased as an alternative at the average factor of 87 % within 1 month of the equivalents delivery at pharmacies.

The investigation was organized by Medco Health Solutions Inc. based in Frankin Lakes, that will be the biggest drug benefit management company in U.S. The company bargains for low rates of prescription drug on behalf of its clients.

In line with the study, Zithromax, the blockbuster of Pfizer Inc. with its annual sales of $1.85 million was quickly taken at pharmacies by universal equivalent at a 90 per cent rate soon after it lost its patent protection in November.

The analysis authors mentioned the replacement of Zithromax, an for respiratory infections, as evidence that more and more doctors order generic types of manufacturer drugs more quickly, even if it's about so-called acute care drugs, such as Zithromax.

The truly good news is why these four common drugs are just the start. With a number of popular medicines expected to go off patent within the next many years, we should see significant prescription drug prices savings - mentioned a senior vice president, Dr. Glen Stettin.

A spokeswoman at Medco, Ann Smith said that over 70 brand name medications, including 19 blockbusters, are losing their patent protection next five years - with total annual sales of $45 million.

If Medcos study shows a trend, in the coming years customers, employers and insurance companies helps you to save vast amounts of dollars in prescription drug - Smith said.

The info met with enthusiastic reaction from consumer groups.

Develop the trend continues. Its good for consumers, revealed Bill Vaughan, senior plan analyst for an group, Consumer Union, located in Washington, D.C.

Vaughan described that past doubts concerning the success and safety of generic drugs have apparently started initially to disappear as society is now more concerned with rapid increase of health-care costs.

The FDA approves these generic drugs because they have already been decided in the same way safe and effective as their brand name counterparts, however, you spend a fraction of the price, Vaughan stated. We think that is very positive and can save yourself consumers literally huge amounts of dollars in the next couple of years.

At once, large pharmaceutical organizations have stated that their brand name drugs won't be replaced by imitations as insurers and doctors know that the brand name drugs promise greater treatment and in consequence - save money.

Hank McKinnell, Pfizer Chairman used that argument throughout last session with analysts in Ny.

In the event that you dont just like the high cost of health care, try the high cost of sickness, McKinnell recommended. The researchers reviewed four drugs: Allegra, Arava, Amaryl and Zithromax. In the second 1 / 2 of 2005, each one of these drugs go out of patent protection. Their common equivalents were ordered as an alternative at a typical factor of 87 % within 30 days of the equivalents delivery at pharmacies.

The study was prepared by Medco Health Solutions Inc. Situated in Frankin Lakes, which is the biggest drug profit management company in U.S. The organization offers for low rates of prescription drug with respect to its clients.

In line with the study, Zithromax, the hit of Pfizer Inc. with its annual sales of $1.85 billion was rapidly replaced at pharmacies by equivalent at a 90 % rate just after it lost its patent protection in November.

The study authors described the substitution of Zithromax, an for respiratory infections, as evidence that more and more doctors propose generic versions of brand name drugs more easily, even though it is about alleged acute care drugs, such as Zithromax.

The truly good news is these four common medicines are only the start. With a number of common medications likely to move off patent within the next a long period, substantial prescription drug costs savings should be seen by us - reported a senior vice president, Dr. Glen Stettin.

A speaker at Medco, Ann Smith stated that more than 70 brand medications, including 19 blockbusters, are losing their patent protection next five years - with total annual sales of $45 million.

If Medcos research shows a long-term trend, in the coming years customers, employers and insurance companies will save billions of dollars in prescription drug - Smith said.

The information met with enthusiastic response from consumer groups.

Hopefully the trend continues. Its good for customers, revealed Bill Vaughan, senior coverage analyst for an group, Consumer Union, situated in Washington, D.C.

Vaughan described that past doubts in regards to the safety and success of common drugs have apparently started initially to disappear as society is now more concerned with rapid increase of health-care costs.

The FDA approves these generic drugs because they have already been determined in the same way safe and effective as their brand counterparts, however you pay a fraction of the cost, Vaughan reported. We think that is very positive and can save yourself customers literally huge amounts of dollars in the next couple of years.

At once, large pharmaceutical businesses have claimed that their brand name drugs won't be substituted by replicas as insurers and doctors recognize that the brand name drugs guarantee greater treatment and in consequence - save money.

Hank McKinnell, Pfizer Chairman used that argument during last session with experts in Nyc.

If you dont such as the high cost of health care, try the high cost of vomiting, McKinnell encouraged.